newsfilter
← Latest News
GlobeNewswire·

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- -- Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 -- -- Multiple clinical trial sites